Navigation Links
Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors. 

Dr. Dhingra, 52, has served as a member of Exosome's board of directors since March 2012.  He has significant experience transforming oncology therapeutic and diagnostic development programs into products available to physicians and patients.  He is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies.  From 1999-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc, including vice president, head, Oncology Disease Biology Leadership team and Head, Oncology Clinical Development. Before joining Roche, he worked at Eli Lilly & Co, and on the faculty of The University of Texas MD Anderson Cancer Center.  During his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as a clinical associate professor at Indiana University School of Medicine and most recently as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center.  Dr. Dhingra also serves on several emerging life science company boards. He previously served on the Boards of several successful companies, including Biovex, Micromet and YM Biosciences, that were acquired by major pharmaceutical companies.  He received his medical training from the All India Institute of Medical Sciences.

"Dr. Dhingra has been a critical contributor to the company since he was first appointed to our Board of Directors last year," said James McCullough , chief executive officer of Exosome Diagnostics. "As we transition toward commercialization in the life sciences and clinical diagnostics markets, we are fortunate to have Dr. Dhingra deep industry experience."

Dr. Dhingra stated, "I am pleased to be asked by the Board to take over as Chairman at this important juncture in the evolution of this company.  Exosome Diagnostics has built a truly exciting platform with the potential to transform the practice of medicine across a variety of therapeutic areas.   I have very much enjoyed working with the Board and the executive team over the past year.   The enormous progress achieved by the company in such a short time has further convinced me that the ability to detect molecular alterations in DNA and RNA contained in the exosomes will play a major role in the future of personalized medicine."

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome diagnostic technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic products for use in companion diagnostic applications, detection, and real-time monitoring of disease. The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
2. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
3. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
4. ResearchMoz.us: MicroRNAs and Exosomes Market Report 2012 - Industry Research Report
5. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
8. S.E.D. Labs to be Acquired by Quest Diagnostics
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):